Tilaknagar Industries reported a consolidated net profit of ₹31.59 crore for the quarter ended June 30, 2026, driven by a 165% year-on-year surge in revenue to ₹2,252.42 crore. This performance marks a sharp recovery from the net loss of ₹14.91 crore recorded in Q4FY26, highlighting the operational impact of its recent acquisitions and integration efforts. The Board of Directors also approved the appointment of Bhumika Batra as an Additional Independent Director and sanctioned a composite scheme of amalgamation for two wholly-owned subsidiaries.

The financial results were reviewed by M/s. Harshil Shah & Company, the statutory auditors, who issued a qualified conclusion. The qualification stems from the company’s failure to carry out an impairment assessment on one of its Ethanol (ENA) plants, despite indications of impairment as required by Ind AS 36. The management maintains that no impairment is necessary as it expects to restart the grain distillery plant after incurring relevant capital expenditure. Additionally, the auditors emphasized a matter regarding the composite scheme of amalgamation between the company and its subsidiaries, which is pending approvals from shareholders, creditors, and the National Company Law Tribunal (NCLT).

Financial Performance

Consolidated revenue from operations jumped to ₹2,252.42 crore in Q1FY26, compared to ₹84.86 crore in Q1FY25. This growth is largely attributable to the inclusion of the Imperial Blue business division, acquired from Pernod Ricard India Private Limited (PRI) in December 2025. The acquisition was completed for a lump-sum cash consideration of ₹3,442 crore, with a deferred consideration of EUR 28 million payable after four years.

While revenue growth was substantial, the net profit declined by 64% year-on-year due to exceptional items. The company incurred non-recurring expenses of ₹30.12 crore in Q1FY26 related to the post-acquisition integration of the Imperial Blue business. These costs include transition and implementation expenses that are not expected to recur in the ordinary course of business. In contrast, Q1FY25 had no such exceptional charges.

Corporate Developments

The Board appointed Ms. Bhumika Batra (DIN: 03502004) as an Additional Independent Director for a three-year term commencing July 27, 2026. Her appointment is subject to shareholder approval within three months. Ms. Batra brings over 22 years of experience in corporate laws, mergers, and acquisitions, and is a Partner with Crawford Bayley & Co. She is not related to any existing directors and is not debarred from holding office.

Furthermore, the Board approved the incorporation of a wholly-owned subsidiary in Nigeria, subject to regulatory approvals under the Foreign Exchange Management Act (FEMA) and Reserve Bank of India guidelines. This move signals the company’s intent to expand its global footprint beyond its current domestic operations.

What the Numbers Show

A critical observation from the filing is the divergence between top-line growth and bottom-line profitability. While revenue more than doubled year-on-year, the net profit fell significantly due to high one-time integration costs. The exceptional item of ₹30.12 crore represents approximately 1.3% of total revenue but consumed nearly half of the pre-tax profit. This suggests that while the acquisition has immediately boosted scale, the normalization of margins will depend on the successful integration of operations and the realization of synergies in subsequent quarters. The absence of tax expense in both periods also indicates that the company may be utilizing tax losses or credits to offset taxable income, a common feature in large-scale restructuring phases.

Tilaknagar Industries reported a consolidated net revenue of ₹1,046 crore for the quarter ended June 30, 2026, marking its first-ever quarterly crossing of the ₹1,000 crore threshold. This represents a 166% year-on-year increase from ₹394 crore in the prior year period, driven by a 172% jump in volumes to 8.7 million cases following the full-quarter impact of the Imperial Blue acquisition. Adjusted profit after tax (PAT), excluding exceptional items and amortization related to the acquisition, rose 52% to ₹76 crore. The company’s net debt increased to ₹2,100 crore from ₹1,911 crore in March 2026 due to complete working capital cycle investments, though management targets net debt below March 2026 levels by March 2027.

The Board of Directors approved the unaudited financial results on July 27, 2026. Statutory auditors Harshil Shah & Company issued a qualified conclusion due to the company's failure to carry out an impairment assessment of one of its ENA plants, despite indications of impairment. This qualification persists from the audited financial statements for the year ended March 31, 2026. Management expects to restart the grain distillery plant after incurring relevant capital expenditure, leading to the belief that no impairment is required.

Financial Performance

Consolidated revenue from operations stood at ₹1,046 crore for the quarter, compared to ₹394 crore in the year-ago period. Adjusted for subsidy income, net revenue was ₹1,026 crore, growing at 189%. EBITDA grew by 79% to ₹169 crore from ₹94 crore. Adjusted for subsidy income, EBITDA stood at ₹148 crore, representing a 166% year-on-year growth with a margin of 14.5%. Excluding the impact of inflationary pressure, the margin would have been approximately 17%.

Profit before tax increased by 9% to ₹96 crore. After accounting for exceptional items totaling ₹30.11 crore related to post-acquisition integration costs for the Imperial Blue business, and tax expenses, the reported net profit was ₹31.59 crore. However, adjusted PAT (excluding exceptional items and amortization on intangible assets related to the acquisition of Imperial Blue) increased by 52% YoY to ₹76 crore.

The following table summarises the key financial metrics for the quarter:

*Excluding exceptional items and amortization related to Imperial Blue acquisition.

Operational Highlights

Volumes grew by 172% year-on-year to reach 8.7 million cases. On a quarter-on-quarter basis, total volumes rose by 9%, led by Imperial Blue (IB), which recorded 17.7% growth. IB expanded its market share across India by approximately 150 basis points quarter-on-quarter, with significant improvements in North, West, and South regions. The brand crossed 2 million cases in both May and June 2026. Mansion House Brandy (MHB) reached 2.6 million cases, reflecting growth of over 7% year-on-year.

Mr. Amit Dahanukar, Chairman & Managing Director, stated that ~90% of IB operations have been transitioned out of the Transition Services & Manufacturing Agreement (TSMA), leaving only one state to be completed. Consequently, exceptional costs relating to the transition are expected to reduce significantly over the remainder of FY27, with average monthly TSMA expenses halving to ~₹8 crore.

Balance Sheet and Debt Structure

The company’s gross debt decreased slightly to ₹2,241 crore from ₹2,295 crore in March 2026, primarily due to a reduction in working capital loans from ₹230 crore to ₹175 crore. However, cash and cash equivalents dropped significantly from ₹384 crore to ₹141 crore, resulting in an increase in net debt to ₹2,100 crore. The term loan component remained stable at ₹2,041 crore. This term loan has a six-year period with a two-year principal moratorium, followed by a balloon repayment structure where 65% of the principal is due in the sixth year. The effective interest rate on the term loan is ~10%-11%.

What the Numbers Show

The significant surge in revenue underscores the successful integration of Imperial Blue. While reported EBITDA margin contracted to 14.5% (adjusted for subsidy) from higher levels in previous periods, this reflects inflationary pressures on packaging inputs, particularly glass. These pressures were partly offset by softened Extra Neutral Alcohol (ENA) prices. Management projects an improvement upon the 15.5% baseline EBITDA margin achieved in Q4 FY26, supported by cost optimization initiatives. The reduction in exceptional integration costs going forward suggests normalized operating margins may be higher than currently reported. Additionally, cost savings from packaging changes and customs reductions under the India-UK FTA are expected to contribute 250–400 basis points in margin expansion on the acquired business.

Corporate Developments

The Board appointed Ms. Bhumika Batra as an Additional Independent Director for a term of three years, commencing July 27, 2026, subject to shareholder approval. Additionally, the Board approved the incorporation of a wholly-owned subsidiary in Nigeria, pending regulatory approvals. The company continues to pursue the Composite Scheme of Amalgamation involving subsidiaries Punjab Expo Breweries Private Limited and Vahni Distilleries Private Limited, awaiting approvals from shareholders, creditors, and the National Company Law Tribunal (NCLT). Tilaknagar also increased its stake in Bartisans to 41.45% through a ₹2 crore primary infusion, aiming to capitalize on the growing cocktail culture and q-commerce momentum.